In this study, to identify common immune subgroups, evaluate how the immune components of the TME regulate therapeutic effectiveness and explore potential strategies to improve the effectiveness of patients with various immune statuses in bladder cancer, we divided patients into four subgroups based on a combination of PD-L1 expression and the type of immune modulation, and then we performed a series of analyses. This evidence concerns the gene CD274 and urinary bladder carcinoma.